Minerva Neurosciences Inc (NERV.OQ)


Minerva Neurosciences, Inc. is a biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS), diseases. The Company’s product candidates are MIN-101, a compound it is developing for the treatment of patients with schizophrenia, and MIN-117, a compound it is developing for the treatment of patients suffering from depressive disorder (MDD). In addition, the Company’s portfolio includes MIN-202, a compound it is co-developing for the treatment of patients suffering from primary and secondary insomnia, and MIN-301, a compound it is developing for the treatment of patients suffering from Parkinson’s disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301.


MIN-101 is a molecule behaving as an antagonist of 5-HT2A and sigma2 receptors, which the Company is developing for the treatment of patients with schizophrenia. MIN-117 is a molecule behaving mainly as an antagonist on 5-HT1A receptors and as an inhibitor of both serotonin and dopamine reuptake, which it is developing for the treatment of patients with MDD. MDD is a subtype and a severe form of depression, with 6% of MDD patients committing suicide. In addition, an available therapy has several side effects, including cognitive impairment, sexual dysfunction and sleep disorders that lead many patients to discontinue therapy. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, which it is developing for the treatment of patients with Parkinson’s disease


MIN-202 is a molecule acting as a selective orexin 2 receptor antagonists, which the Company is co-developing for the treatment of patients with insomnia. Insomnia can be the primary condition for patients or a secondary symptom of another medical or psychiatric condition, such as MDD or schizophrenia. It intends to evaluate MIN-202 as a treatment in pri mary insomnia, as well as secondary insomnia as an adjunctiv! e therapy with an antidepressant for the treatment of mood disorders. Unlike many therapies that activate sleep-promoting neurotransmitters, MIN-202 is specifically targeted towards inhibiting the activity of the neurons that promote wakefulness. The Company is co-developing MIN-202 with Janssen Pharmaceutica N.V.

Leave a Reply

Your email address will not be published. Required fields are marked *